TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00620893

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PEG- 400 based artificial tear
Description: Baseline: Instill one drop in the randomized eye four times daily starting the day after surgery can be used more frequently if needed Month 3: Instill one drop in the randomized eye twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Systane
Description: Baseline: Instill one drop in the randomized eye four times daily starting the day after surgery can be used more frequently if needed Month 3: Instill one drop in the randomized eye twice daily
Study: NCT00262392

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pamidronate (AREDIA)
Description: Pamidronate (AREDIA) vs radiation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pamidronate (AREDIA)
Description: Pamidronate (AREDIA) vs radiation
Study: NCT03089515

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cardio-Pulmonary Exercise Testing (CPET)
Description: This test helps determine if the decreased tolerance to exercise or shortness of breath with activity a patient is experiencing is caused by a cardiac disease, versus a pulmonary disease.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cardio-Pulmonary Exercise Testing (CPET)
Description: This test helps determine if the decreased tolerance to exercise or shortness of breath with activity a patient is experiencing is caused by a cardiac disease, versus a pulmonary disease.
Study: NCT00354835

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Given IV
Study: NCT03650608

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cohort 2: HL217 Ophathalmic Solution BID
Description: Cohort 2 (Twice a day)
Study: NCT04327648

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Social interaction treatment
Description: Children in social interaction treatment group will have 30min social interaction each day for 3 months.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Neuronal cognition treatment
Description: Children in neuronal cognition treatment group will experienced neural cognition training 30min each day for 3 months.
Study: NCT00354835

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study: NCT03650608

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cohort 3: HL217 Ophthalmic Solution QID
Description: Cohort 3 (Four times a day)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Ophthalmic solution
Description: Placebo
Study: NCT04327648

Intervention type: OTHER
Group type: OTHER
Intervention: Routine treatment
Description: Children in routine treatment group will keep the same initial treatment.
Study: NCT01573793

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Parenting Education
Description: Will receive parenting educational materials hypothesized to enhance emotional and cognitive development

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Control Group - Safety Materials
Description: Will receive safety and dental hygiene materials that have no bearing on emotional and cognitive development
Study: NCT03019588

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: IV infusion
Study: NCT00354835

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Dactinomycin
Description: Given IV
Study: NCT02269605

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Group 1: Placebo (sodium chloride 0.8 %) at single dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bryostatin 1 (10ug/m2)
Description: Group 2: Bryostatin 1 (10ug/m2) at single dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bryostatin 1 (20ug/m2)
Description: Group 3: Bryostatin 1 (20ug/m2) at single dose
Study: NCT02958527

Intervention type: DRUG
Intervention: venlafaxine
Description: The usual adult starting dosage for oral use is 37.5 mg of venlafaxine once daily, which is increased to 75 mg once daily after a meal from 1 week later. The dose may be adjusted within a range not exceeding 225 mg/day according to the patient's age and symptoms. However, the dose should be increased by 75 mg/day at intervals of not less than 1 week.
Study: NCT00142597

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Acupuncture
Description: Involves the insertion and manual stimulation of thin acupuncture needles into specific points in the body.~Fibromyalgia participants will be randomized to receive 9 acupuncture treatments over the course of four weeks.~All participants will be scanned twice using the fMRI scanner. The PET portion of the study is optional.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham treatment
Description: Fibromyalgia participants will be randomized to receive 9 sham treatments over the course of four weeks.~All participants will be scanned twice using the fMRI scanner. The PET portion of the study is optional.
Study: NCT03033212

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapist-Guided Rehabilitation
Description: Rehabilitation consists of exercises guided by a certified physical therapist. These exercises include: aerobics, walking tests, stability exercises, and strengthening exercises.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapist-Guided Rehabilitation
Description: Rehabilitation consists of exercises guided by a certified physical therapist. These exercises include: aerobics, walking tests, stability exercises, and strengthening exercises.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Self-Guided Rehabilitation
Description: Rehabilitation consists of self-guided exercises with provided instructions. These exercises include: aerobics, walking tests, stability exercises, and strengthening exercises.
Study: NCT03472677

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ice Pack and Cooling Device
Description: A comparison of two cooling methodologies in healthy volunteers after single intra-articular (IA) injection (15 mL) of 2% lidocaine (without epinephrine).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNTX-4975-05 (trans-capsaicin)
Description: Controlled cooling wrap vs ice pack cooling after single IA injection of 1 mg CNTX-4975-05 in each arm after single IA (15 mL) injection of 2% lidocaine (without epinephrine).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNTX-4975-05 (trans-capsaicin)
Description: Controlled cooling parameters will be determined after evaluation of data from prior Cohort(s) after single IA injection (15 mL) of 2% lidocaine (without epinephrine) and single IA injection of 1 mg CNTX-4975-05.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNTX-4975-05 (trans-capsaicin)
Description: Controlled cooling with knee device vs no cooling (determined after evaluation of data from previous cohorts) after single IA injection (15 mL) of 2% lidocaine (without epinephrine) and single IA injection of 1 mg CNTX-4975-05.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capsaicin
Description: Four intradermal injections of capsaicin, two on each forearm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capsaicin
Description: Four intradermal injections of capsaicin, two on each forearm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capsaicin
Description: Four intradermal injections of capsaicin, two on each forearm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capsaicin
Description: Four intradermal injections of capsaicin, two on each forearm.
Study: NCT01356485

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MP4CO
Description: 43 mg/mL pegylated carboxyhemoglobin \[≥ 90% CO hemoglobin saturation\] in physiological acetate electrolyte solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium chloride solution
Description: Normal saline (0.9% sodium chloride solution)
Study: NCT00922051

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation (TENS)

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Transcutaneous electrical nerve stimulation (TENS)
Description: Placebo
Study: NCT01938937

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial bright light device

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial sham device
Study: NCT04351971

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention Group
Description: The patient's position is in the supine position. The therapist identifies the arches of the atlas and positions one hand at this level with the fingers extended. The other hand is located in the occipital region. Subsequently, the therapist makes a pressure with his shoulder assessing the movement and applies a pressure to the back. This technique is performed by mobilization cycles of 15 seconds and 3 seconds of rest for a total period of 5 minutes.The patient's position is in the supine position. The therapist identifies the arches of the atlas and positions one hand at this level with the fingers extended. The other hand is located in the occipital region. Subsequently, the therapist makes a pressure with his shoulder assessing the movement and applies a pressure to the back. This technique is performed by mobilization cycles of 15 seconds and 3 seconds of rest for a total period of 5 minutes.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Placebo group
Description: The technique consists of placing the patient in the supine position, one hand is located in the arches of the atlas, the other hand is located in the occipital. The therapist's shoulder is located in the anterior region. This position is maintained for 5 minutes without exerting pressure.
Study: NCT01309191

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Minoxidil
Description: Over the counter Rogaine, twice a day for 8 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01993758

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Low tourniquet pressure
Description: Tourniquet pressure set as 120mmHg above the systolic blood pressure just before tourniquet inflation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional tourniquet pressure
Description: Tourniquet pressure set as 150mmHg above the systolic blood pressure just before tourniquet inflation
Study: NCT02466581

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sulphasalazine + Hydroxychloroquine OR Prednisolone
Description: Methotrexate: 25mg/week. SSZ: 2 g/day. HCQ: 35 mg/kg/week (Finland and Denmark) Methotrexate: 25mg/week. Prednisolone 20 mg/day tapered in 9 weeks to 5 mg/day, discontinued after 9 months. (Sweden, Norway, and Iceland)
Study: NCT03942614

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nordic pole walking
Study: NCT03304951

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sinopsys® Lacrimal Stent
Description: The Sinopsys® Lacrimal Stent is indicated for use in creating a transcaruncular ethmoid access.
Study: NCT04166396

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Resveratrol
Description: 500 mg resveratrol, BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Resveratrol
Description: 500 mg resveratrol, BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NR
Description: 500 mg NR BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NR
Description: 500 mg NR BID

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study: NCT04166396

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study: NCT02466581

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Cimzia
Description: Certolizumab-pegol: 200 mg s.c. every other week. Methotrexate: 25mg/week

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Cimzia
Description: Certolizumab-pegol: 200 mg s.c. every other week. Methotrexate: 25mg/week
Study: NCT04449029

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be available as a clear colorless solution for injection to be administered subcutaneously once weekly.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be available as a clear colorless solution for injection to be administered subcutaneously once weekly.
Study: NCT00354835

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dactinomycin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan Hydrochloride
Description: Given IV

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation Therapy
Description: Undergo radiotherapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vincristine Sulfate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate
Description: Given IV
Study: NCT00636545

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oblimersen (Genasense)
Description: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oblimersen (Genasense)
Description: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oblimersen (Genasense)
Description: Intravenous
Study: NCT03581097

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Video Group
Description: Patients in the film group watched the film using a laptop computer equipped with headphones, and Visual Analog Pain Scale (VAS) was repeated after the movie. Video was recorded by the Anaesthesiology department team, in order to explain and show in a detailed way on a model, the sequence of events, which occurs between the arrival of patients in the operating room and the performance of Intra-Venous Regional Anesthesia (IVRA)
Study: NCT03049748

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mobile phone app (VAD Care App)
Description: VAD Care App is a novel self-management tool being tested for patients with implantable LVADs. The app has daily push notifications (alerts), cues for daily self-management tasks, two-way communication using text messages and videoconferencing (virtual clinic), and links to LVAD self-management skills and videos easily accessible for self-management skill review.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual LVAD Care
Description: Routine clinic follow-up visits over 6 months. Patients and caregivers will both receive self-management education post discharge and as needed throughout the duration of the study.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual LVAD Care
Description: Routine clinic follow-up visits over 6 months. Patients and caregivers will both receive self-management education post discharge and as needed throughout the duration of the study.
Study: NCT01882686

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Classification Based Cognitive Functional Therapy
Description: A novel multidimensional classification system has been developed incorporating the biopsychosocial model, which subgroups patients based on their presentation. This subclassification is the base for matched interventions directed at the maladaptive cognitive, physical and lifestyle behaviours associated with the disorder. The intervention is called 'cognitive functional therapy' as it directly challenges these behaviours in a functionally specific and graduated manner.
Study: NCT03115957

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Parenteral Nutrition
Description: Patients who can not tolerate 30% of target energy EN will receive supplemental parenteral nutrition at day 3 or at day 8 after abdominal surgery.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Parenteral Nutrition
Description: Patients who can not tolerate 30% of target energy EN will receive supplemental parenteral nutrition at day 3 or at day 8 after abdominal surgery.
Study: NCT02224586

Intervention type: DEVICE
Intervention: light treatment
Description: clinical routine treatment according to the doctor's advice
Study: NCT04099758

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness of the breath meditation
Description: A 10-minute mindfulness of the breath meditation practice

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Audio-recording control
Description: 10 minute non-fiction audio-recording delivered online
Study: NCT03746795

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spirometric examinations realized using the EIT
Description: Spirometric examinations will be realized using the EIT alone.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Simultaneous measurement by spirometer and EIT
Description: Spirometric examinations will be realized using the simultaneous measurement by spirometer and EIT
Study: NCT03359863

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pirfenidone
Description: Subjects will receive pirfenidone for 52 weeks, titrated to 2403 mg/day (3 capsules, 3× daily) after a 4-week titration period (1 capsule, 3x daily for 2 weeks, 2 capsules, 3x daily for 2 weeks) for a total of 56 weeks of pirfenidone. Eligible participants will continue pirfenidone beyond 56 weeks.
Study: NCT01261663

Intervention type: OTHER
Intervention: oral nutritional energy and protein enriched supplement (NOS)
Study: NCT01368380

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychological intervention
Description: Couples in the intervention group attends six to eight couple-sessions performed by a psychologist.
Study: NCT00919737

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NPC-08
Description: Polifeprosan 20 with Carmustine 3.85%
Study: NCT04467151

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anti-SARS-CoV-2 plasma
Description: Administration of anti-SARS-CoV-2 convalescent plasma

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administration of placebo (albumin 5%)
Study: NCT02629393

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ORGN001 (formerly ALXN1101)
Study: NCT04332549

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PICS (Reconstitution Method 1 or 2)
Description: dose: 260mg/m2 Frequency: 2 period cross over study Route of administration : intravenous infusion duration of therapy: 2 cycles of PICS

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PICS (Reconstitution Method 1 or 2)
Description: dose: 260mg/m2 Frequency: 2 period cross over study Route of administration : intravenous infusion duration of therapy: 2 cycles of PICS
Study: NCT04449029

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be available as a clear colorless solution for injection to be administered subcutaneously once weekly.
Study: NCT02466581

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Orencia
Description: Abatacept: 125 mg s.c. every week. Methotrexate: 25mg/week
Study: NCT02236624

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Study: NCT02466581

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Orencia
Description: Abatacept: 125 mg s.c. every week. Methotrexate: 25mg/week

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: RoActemra
Description: Tocilizumab is given as 4-weekly infusions at dosage 8 mg/kg or 162 mg in solution s.c. every week. Methotrexate: 25mg/week

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: RoActemra
Description: Tocilizumab is given as 4-weekly infusions at dosage 8 mg/kg or 162 mg in solution s.c. every week. Methotrexate: 25mg/week
Study: NCT01793922

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PD
Description: pneumodilation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: POEM
Description: peroral endoscopic myotomy
Study: NCT03624036

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: brexucabtagene autoleucel
Description: CAR-transduced autologous T cells administered intravenously

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: brexucabtagene autoleucel
Description: CAR-transduced autologous T cells administered intravenously

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: brexucabtagene autoleucel
Description: CAR-transduced autologous T cells administered intravenously

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: brexucabtagene autoleucel
Description: CAR-transduced autologous T cells administered intravenously

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: brexucabtagene autoleucel
Description: CAR-transduced autologous T cells administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Administered intravenously
Study: NCT02708706

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hyaluronic acid (hyruan)
Description: 2cc hyaluronic acid

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: physical therapy
Description: patient received traditional physical therapy, including therapeutic exercise and stretch exercise

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: physical therapy
Description: patient received traditional physical therapy, including therapeutic exercise and stretch exercise